Table 2 General characteristics and clinical outcomes of the 16 patients with GBS after MI
From: Guillain–Barre syndrome after myocardial infarction: a case report and literature review
Varible | Total (n = 16) | Prognosis | |
|---|---|---|---|
Good (n = 13) | Died (n = 3) | ||
Male | 14(87.5) | 12(92.3) | 2(66.7) |
female | 2(12.5) | 1(7.3) | 1(33.3) |
Clinical manifestations | |||
Limb weakness | 15(93.7) | 12(92.3) | 3(100) |
Quadriparesis | 11(68.8) | 9(69.2) | 2(66.7) |
Paresthesia | 13(81.2) | 10(76.9) | 3(100) |
Papilloedema | 1(6.25) | 1(7.7) | 0 |
Unilateral facial paralysis | 2(12.5) | 2(15.4) | 0 |
Bilateral facial paralysis | 3(18.8) | 3(23.1) | 0 |
Autonomic disfunction | 3(18.8) | 3(23.1) | 0 |
Dysphagia | 4(25) | 2(15.4) | 2(66.7) |
Dyspnoea | 9(56.3) | 7(53.8) | 2(66.7) |
Treatment for GBS | |||
Immunoglobulin | 5(31.3) | 3(23.1) | 2(66.7) |
Plasmapheresis | 3(18.8) | 2(15.4) | 1(33.3) |
Plasmapheresis + immunoglobulin | 1(6.25) | 0 | 1(33.3) |
Corticosteroids | 3(18.8) | 2(15.4) | 1(33.3) |
Other | 4(25) | 4(30.8) | 0 |
Treatment for MI | |||
Streptokinase | 5(31.3) | 4(30.8) | 1(33.3) |
Surgery | 4(25) | 2(15.4) | 2(66.7) |
Surgery + Streptokinase | 2(12.5) | 2(15.4) | 0 |
Other | 2(12.5) | 2(15.4) | 0 |
Nil | 3(18.8) | 3(23.1) | 0 |
Type of MI | |||
Anterior | 6(37.5) | 5(38.5) | 1(33.3) |
Inferior | 7(43.8) | 6(46.2) | 1(33.3) |
Posterior | 1(6.25) | 1(7.7) | 0 |
Anterior + inferior + posterior | 1(6.25) | 0 | 1(33.3) |
Nil | 1(6.25) | 1(7.7) | 0 |
ST-segment elevation MI | 8(50) | 7(53.8) | 1(33.3) |
MV | 9(56.3) | 7(53.8) | 2(66.7) |